Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 2, Issue 1, 2005, Pages 20-21

  Rosati, Gerardo ^a  

^a SAN CARLO HOSPITAL   (Italy)

Author keywords

Cetuximab; Colorectal cancer; Epidermal growth factor receptor; Monoclonal antibody

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; HUMAN; METASTASIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHORT SURVEY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; CANCER STAGING; DATA ANALYSIS; DRUG EFFICACY; KIDNEY FUNCTION; LIVER FUNCTION; MEDICAL DOCUMENTATION; MONOTHERAPY;

EID: 20444455060     PISSN: 17434378     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpgasthep0066     Document Type: Short Survey

References (5)

1. Herbst RS and Shin DM (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94: 1593-1611
2. Saltz L et al. (2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) (abstr 7). Proc Am Soc Clin Oncol 20: 3a
3. Saltz L et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Onco 22: 1201-1208
4. Ellis LM and Hoff PM (2004) Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. J Clin Oncol 22: 1177-1179
5. Tabernero JM et al. (2004) An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results (abstr 3512). Proc Am Soc Clin Oncol 23: 248